Kornimate/medical-research-clean huggingface dataset:
interpretation bias modification for body dysmorphic disorder

Conditions: Body Dysmorphic Disorder

Summary: the purpose of this study is to determine whether a computerized intervention designed to reduce appearance and evaluation related interpretation biases will reduce symptoms associated with body dysmorphic disorder.

the present study aims to examine the feasibility of a remote treatment for body dysmorphic disorder delivered via the internet. to evaluate the efficacy of the ibm protocol we have developed in reducing negative appearance and evaluative related interpretations, we will conduct a two-arm randomized controlled trial over the internet. individuals with a diagnosis of body dysmorphic disorder (n = 40) will be randomized to one of two conditions: 1) ibm or 2) progressive muscle relaxation. each condition will consist of eight 10-25 minute treatment sessions. participants will complete two sessions per week for four weeks and will be administered assessments at pre-treatment, one week post-treatment and at 3-month follow-up. we hypothesize that: 1) ibm will lead to greater reductions in bdd symptoms than the pmr condition; 2) ibm will lead to greater reductions in depression, anxiety and suicidal ideation than the pmr condition; 3) ibm will lead to greater reductions in threat interpretations and greater increases in benign interpretations than the pmr condition; 4) the effects of condition on bdd symptoms will be mediated by changes in bdd-related interpretation bias; and 5) the effects of training in the ibm condition will be maintained at the 3-month follow-up assessments.

Eligibility criteria:
inclusion criteria: * current diagnosis of body dysmorphic disorder according to dsm-5 criteria * bdd-ybocs score greater than or equal to 20 * fluent in english * no significant physical defect or flaw in appearance (e.g., disfiguration) exclusion criteria: * history of psychotic disorder, bipolar disorder, borderline personality disorder * current substance use disorder * unstable medication status (i.e. change in medication within the last month) * concurrent psychotherapy for appearance concerns * active and clinically significant suicidality
study of health behavior in patients after heart valve replacement： longitudinal studies

Conditions: Heart Valve Diseases; Health Behavior; Postoperative Period

Summary: to investigates the influencing factors and the pathways of health behavior in patients after heart valve replacement.

currently, the prevalence of heart valve disease is 2.0% to 13.2%, and heart valve replacement is the most important treatment to address heart valve disease. heart valve replacement surgery is highly traumatic and risky, and the recovery of physiological, psychological, and social functions of postoperative patients is challenging, affecting the recovery process of patients. healthy behavior is a lifestyle that can effectively reduce risk factors for adverse events and complications at the physiological, psychological, and social levels to slow disease progression, which can help promote patient recovery and improve prognosis. therefore, this study investigates and analyzes the health behaviors of postoperative patients in different periods, explores their influencing factors and analyzes their pathways of action.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. vhd diagnosed by echocardiography; 3. received hvr treatment; 4. able to communicate normally. exclusion criteria: 1. those with a conscious disorder or mental illness; 2. those with severe organic diseases or comorbidities; 3. those with cardiac function class iv; 4. those who could not complete the questionnaire correctly independently or under the guidance of the researcher.
comparison study of isv-303 to durasite vehicle in cataract surgery subjects

Conditions: Ocular Inflammation

Summary: the purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of isv-303 compared with durasite vehicle.


Eligibility criteria:
inclusion criteria: * male or female subjects age 18 or older scheduled for unilateral cataract surgery with posterior chamber intraocular lens implantation * if a female is of childbearing potential, the subject must agree to and submit a negative pregnancy test before any protocol-specific procedures are conducted. the subject must use effective contraception for the duration of the study. post menopausal is defined as having no menses for at least 12 consecutive months * signature of the subject on the informed consent form * willing to avoid disallowed medication for the duration of the study. * willing and able to follow all instructions and attend all study visits * able to self-administer study drug (or have a caregiver available to instill all doses of study drug) * additional inclusion criteria also apply exclusion criteria: * known hypersensitivity or poor tolerance to bromfenac sodium or any component of the study medications or any of the procedural medications * currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive pregnancy test * currently suffer from alcohol and/or drug abuse * prior (within 30 days of beginning study treatment) or anticipated concurrent use of an investigational drug or device * a condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation * additional exclusion criteria also apply
feasibility study for abused chinese immigrant women

Conditions: Intimate Partner Violence; Depression; Anxiety; PTSD

Summary: intimate partner violence (ipv) is a serious social and public health issue. in the u.s., more than 1 in 3 women experience physical or sexual violence, and/or stalking by an intimate partner during their lifetime. ipv has significant physical and mental health consequences such as injury, chronic pain, and depression. chinese immigrants have been overlooked and underserved and represent an especially vulnerable group of ipv victims, as they are less likely to seek help through ipv service agencies, women's shelters, hospitals, or law enforcement. effective ipv intervention programs that are culturally appropriate, accessible, and acceptable are essential to this underserved population. however, no studies have been conducted with abused chinese immigrant women to help them deal with ipv and reduce mental health consequences. therefore, the study adapted a structured ipv intervention from the domestic violence enhanced home visitation program (dove) as well as incorporate self-compassion and relaxation techniques for chinese immigrant women experiencing ipv. the intervention is called self-compassion, health, and empowerment (she). the study will test the feasibility and acceptability of the she to reduce ipv and improve mental health well-being for abused chinese immigrant women residing in the us.


Eligibility criteria:
inclusion criteria: * 18 years or older and female, self-identify as chinese, reside in the u.s., have been in an intimate relationship at time of participation, and have experienced ipv within the current relationship. exclusion criteria: * women are excluded if they report substance use or suicidality or having been in mental health care for severe mental illness.
phase 3 study of carfilzomib, melphalan, prednisone vs bortezomib, melphalan, prednisone in newly diagnosed multiple myeloma

Conditions: Multiple Myeloma

Summary: the primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (cmp) or with velcade® (bortezomib), melphalan and prednisone (vmp).


Eligibility criteria:
inclusion criteria: 1. newly diagnosed symptomatic multiple myeloma (per international myeloma working group \[imwg\] diagnostic criteria) 2. transplant ineligibility 3. measurable disease, as defined by 1 or more of the following (assessed within 21 days prior to randomization): * serum m-protein ≥ 0.5 g/dl, or * urine m-protein ≥ 200 mg/24 hours, or * in subjects without detectable serum or urine m-protein, serum free light chain (sflc) \> 100 mg/l (involved light chain) and an abnormal kappa lambda ratio (sflc kappa lambda ratio \ 1.65) 4. no prior treatment for multiple myeloma 5. eastern cooperative oncology group (ecog) performance status 0-2 exclusion criteria: 1. multiple myeloma of igm (immunoglobulin m) subtype 2. glucocorticoid therapy within 14 days prior to randomization that equals or exceeds a cumulative dose of 160 mg of dexamethasone 3. poems syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 4. plasma cell leukemia (\> 2.0 × 10\^9/l circulating plasma cells by standard differential) 5. waldenström macroglobulinemia (wm) 6. known amyloidosis
reducing anxiety levels through the dharma life app-based and mentor-based program targeting personality characteristics: a randomized control trial

Conditions: Anxiety

Summary: the purpose of this study was to examine whether an app- and mentor-based program reduced anxiety among individuals reporting difficulties with anxiety. for the intervention group, this study involved completing an 8-week program focused on helping participants reach their personality goals. the program involved app-based games, journaling, and completing behavioral challenges. participants engaged with the study app for approximately 15 minutes per day and spoke with a study mentor weekly for 1 hour. participants were asked to complete surveys prior to and after the program. the pre-program survey lasted approximately 1 hour, and the post-program survey lasted approximately 30 minutes. for the control group, this study involved completing surveys. participants were asked to complete surveys 8 weeks apart. the first batch of surveys lasted approximately 1 hour, and the follow-up surveys lasted approximately 30 minutes.


Eligibility criteria:
inclusion criteria: * moderate to severe anxiety levels based on the bai and gad-7 exclusion criteria: * we excluded participants experiencing any of the following self-reported behaviors in the past 6 months: substance abuse, self-harm, harm or destruction of another person or their property, suicidal ideations, and feeling helpless after the death of a loved one
an early warning model for assessing the onset, progression and sequelae of covid-19

Conditions: COVID-19

Summary: based on the characteristics of symptoms, differences in physical and chemical examinations and tests, and characteristics of traditional chinese medicine (tcm) disease differentiation and syndrome differentiation, the evaluation indicators for the clinical early warning model were screened, and the "three-level early warning mechanism for covid-19 patients at high risks, with progression to severe cases and sequelae was constructed.

adopt multi-level evidence base architecture, build "multi-source data analysis, feature extraction, multi-level evidence extraction, active the integrated chinese and western medicine big data platform integrates the original evidence processing into a multi-level evidence base, comprehensive analysis of the platform will generate a multi-level evidence base by processing the original evidence, analyze the evaluation indexes of new coronary pneumonia, select the features, build a deep neural network model, train and validate the model, and establish a high the model is trained and validated, and a three-level early warning model is established for people at high risk of new coronary pneumonia, those who turn serious, and those with sequelae.

Eligibility criteria:
inclusion criteria: 1. meeting the diagnostic criteria of mild and moderate types of covid-19 disease described in the "diagnostic and treatment protocol for novel coronavirus pneumonia (trial version 9)" \[9\]; 2. age ≥18 years old and ≤90years old; 3. not more than 5 days after the occurrence of the first symptom (or confirmed onset); 4. the subject agrees to participate the study and have signed the informed consent form by paper signature, electronic signature of mobile software or voice authorization. exclusion criteria: 1. pregnant or lactating women; 2. patients complicated with severe heart, liver, kidney, blood system and other primary diseases and mental disorders. 3. patients with disturbance of consciousness, aphasia, dementia and other conditions that prevent them from cooperating with the clinical investigators 4. patients with incomplete study data.

Keywords: early warning model
duodenal exclusion for the treatment of t2dm

Conditions: Diabetes

Summary: evaluation of duodenal exclusion procedure for the treatment of t2dm


Eligibility criteria:
inclusion criteria: 1. age between 20 and 65 years 2. bmi between 23 and 34 3. oral agents or insulin to control t2dm 4. inadequate control of diabetes as defined as hba1c \>/ 7.5 5. understanding of the mechanisms of action of the treatment exclusion criteria: 1. more than 10 years of t2dm diagnosis 2. more than 7 years of insulin use 3. previous abdominal operations 4. coagulopathy 5. liver cirrhosis 6. unable to comply with study requirements, follow-up schedule or give valid consent. 7. currently pregnant.
tikeasy tablet satisfaction (tiktac)

Conditions: Old Age; Debility; Satisfaction

Summary: in the last ten years, gerontechnology is becoming an increasing topic in geriatric medicine. nevertheless, there are still few studies assessing the usability of technologies in old patients, especially when they are hospitalized. moreover, it has been shown that new technologies could be a source of ageism, thence the importance of involving the old people in the development of these technologies. tik easy is a subsidiary of la poste company. tik easy as designed a new tablet pc for old people. research tends to show that the use of tablet pc can promote health and well-aging, and delay cognitive decline. in this study, we want to give a free access to "ardoiz", the tablet pc designed by tik easy, for old patients hospitalized in a geriatric acute care unit. the "ardoiz" tablet pc allows to: * maintain the family and social bond (send and receive messages, share photos and videos, call remotely between the patient and his family) * discovering the internet at his own pace (browse the internet with daily updated contents such as news, content on cooking, music, etc.). * prevent cognitive aging (stimulate cognitive abilities with the dynseo games). * facilitate online administrative procedures.

the "ardoiz" tablet pc will be given to old patients hospitalized in the acute care geriatric unit of the university hospital of angers. patients and their relatives will have a free access to "ardoiz" during their hospitalisation. the maximum duration of use will be 9 days. after the using period, a survey will be proposed to the patients and their relatives. this survey include questions concerning usability (using the validated sus questionnaire), ergonomics (using non validated specific questionnaire with closed questions oriented on "ardoiz" device), satisfaction (general and specific questions using non validated questionnaire with forced choice likert scale in 4 points and closed questions). after recruiting all expected patients and relatives; the survey will also be submitted to the professional caregivers of the unit.

Eligibility criteria:
inclusion criteria: * patients : * aged 65 years old and over * to be hospitalised in geriatric medicine department of angers university hospital * caregivers: * family members or relatives * aged 18 years old and over * healthcare team : * geriatric medicine department's staff of angers university hospital * aged 18 years old and over exclusion criteria: * patients : * existence of a delirium revealed by the confusion assessment method * to be under legal protection * refusal of participating

Keywords: old poeple elderly usability ergonomy tablet pc
post marketing clinical follow up study for magnetos putty in patients with degenerative disc disease

Conditions: Degenerative Disc Disease

Summary: this study is a post-marketing clinical follow-up study for magnetos putty. magnetos putty is a synthetic bone-like material which is routinely used by surgeons as a treatment for patients with degenerative disc disease who will undergo surgery for spinal fusion (extreme lateral interbody fusion (xlif). magnetos putty will be used according to the instructions for use.


Eligibility criteria:
inclusion criteria: 1. written informed consent by the patient. 2. male or female patient ≥ 25 up to and including 75 years old. 3. patients with degenerative disc disease with up to grade 1 spondylolisthesis and with leg pain requiring 1 to 3 level laminectomy and a single/two-level fusion (l2 - s1). degenerative disc disease is defined by the presence of one or more of the following: 1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs), 2. osteophyte formation of facet joints or vertebral endplates, 3. decreased disc height by \> 2 mm, but dependent upon the spinal level, 4. scarring/thickening of ligamentum flavum, annulus fibrosis or facet joint capsule, 5. disc degeneration and/or herniation, 6. facet degeneration, 7. vacuum phenomenon. 4. patients with an oswestry disability index (odi) score ≥ 30. 5. patients with a visual analogue scale (vas) leg score ≥ 40. 6. failed conservative treatment (physical therapy, bed rest, medications, spinal injections or transcutaneous electrical nerve stimulation) for a period of 6 months prior to study enrollment. exclusion criteria: per the current instruction for use, magnetos putty must not be used in the following clinical situations: 1. to treat conditions in which general bone grafting is not advisable. 2. in conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilisation is not possible). 3. in case of significant vascular impairment proximal to the graft site. 4. in case of severe metabolic or systemic bone disorders that affect bone or wound healing. 5. in case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis). 6. when intraoperative soft tissue coverage is not planned or possible. 7. in direct contact with the articular space. 8. in case of treatment with medication interfering with the calcium metabolism.

Keywords: spinal fusion
phase ii pap plus gm-csf versus gm-csf alone for non-metastatic prostate cancer

Conditions: Prostate Cancer

Summary: the investigators are trying to find new methods to treat prostate cancer. the approach the investigators are taking is to try to enhance patients' own immune response against the cancer. in this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body fight prostate cancer.


Eligibility criteria:
inclusion criteria: * histologic diagnosis of adenocarcinoma of the prostate * completion of local therapy by surgery and/or ablative radiation therapy at least 3 months prior to entry, with removal or ablation of all visible disease, including seminal vesical and/or local lymph node involvement * rising prostate specific antigen (psa) levels without scan evidence of metastatic disease * asymptomatic or mildly symptomatic and life expectancy of at least 4 months exclusion criteria: * small cell or other variant prostate cancer histology * evidence of immunosuppression * prior treatment with androgen deprivation except if given neoadjuvantly or adjuvantly with radiation therapy or at time of prostatectomy. in this situation, no more than 24 months of androgen deprivation must have been given and treatment must not have been within 12 months prior to screening for this study. * serum testosterone at screening \< 50 ng/dl * known bone metastases or lymph node involvement as determined by bone scan or computed tomography (ct) scan of the abdomen and pelvis within 4 weeks of study entry * prior vaccine therapy for prostate cancer * known allergic reactions to granulocyte-macrophage colony-stimulating factor (gm-csf) * severe intercurrent medical conditions or laboratory abnormalities that would impart, in the judgment of the medical monitor, excess risk associated with study participation or study agent administration
a comparison of symbicort® pmdi with budesonide hfa pmdi in african american subjects with asthma.

Conditions: Asthma

Summary: the purpose of this study is to determine the effectiveness and safety of symbicort® pmdi (a medication approved by the food and drug administration, fda) in the african american population.


Eligibility criteria:
inclusion criteria: * male or female, african american (self-reported), ≥12 years of age * moderate to severe asthma requiring treatment with an inhaled corticosteroid * diagnosis of asthma for at least 6 months exclusion criteria: * subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular) * any significant disease or disorder that may jeopardize a subject's safety

Keywords: moderate asthma severe asthma
pet study of acetylcholine esterase activity in alzheimer's disease

Conditions: Alzheimer Disease

Summary: the aim of this study is to understand regional variations in acetylcholine esterase activity in alzheimer's disease. in this study the aim is to identify by pet the physiological values of the regional activity of acetylcholine esterase using the 11c pm4 tracer and to study by pet and 11c pm4 the brain activity of acetylcholine esterase in a group of patients with alzheimer's disease, enrolled according to the inclusion and exclusion criteria. the pet data will be correlated with the clinical, neuropsychological and morphological data acquired by mri and with the clinical-cognitive outcome.


Eligibility criteria:
inclusion criteria: * patients diagnosed with alzheimer's disease; * patients must have undergone an instrumental morphological examination to exclude other neurological pathologies. exclusion criteria: * positive history of major head trauma; * clinically active somatic diseases.
evaluation of a new metal biliary stent of 12-mm diameter: a case control study

Conditions: Malignant Biliary Obstruction

Summary: biliary stent allows the drainage of the bile ducts palliatively or preoperatively in the event of malignant biliary stenosis, and a biliary calibration in the event of benign stenosis. currently, by expert agreement, the diameter is 10-mm for metal stent. since 2017, larger stents have been marketed in france and are approved for the biliary drainage of benign and malignant biliary stricture. these new 12-mm diameter stent could reduce the risk of recurrent biliary obstruction (rbo) and therefore increase the stent duration. the aim of our study was to compare whether the permeability of 12-mm diameter stent was better than a conventional 10-mm, covered or uncovered prosthesis depending on the indication.


Eligibility criteria:
inclusion criteria: * benign and malignant biliary stricture of the lower or median portion of the main biliary duct with indication of biliary stent placement including pre-operatively drainage * age≥ 18 years old; * karnofsky score ≥ 40. exclusion criteria: * hilar stenosis; * coagulation disorder (pt \<50%, platelets \< 80,000).

Keywords: biliary stent malignant biliary stenosis